Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in chronic low back pain
NCT02620020Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of fasinumab in chronic low back pain (CLBP), sponsored by Regeneron Pharmaceuticals. Started Jan 2016; status: completed.
02
Drugs
fasinumab
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT02620020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620020.